CY1122976T1 - Μαλακες καψουλες καλσιφεδιολης - Google Patents

Μαλακες καψουλες καλσιφεδιολης

Info

Publication number
CY1122976T1
CY1122976T1 CY20201100484T CY201100484T CY1122976T1 CY 1122976 T1 CY1122976 T1 CY 1122976T1 CY 20201100484 T CY20201100484 T CY 20201100484T CY 201100484 T CY201100484 T CY 201100484T CY 1122976 T1 CY1122976 T1 CY 1122976T1
Authority
CY
Cyprus
Prior art keywords
soft capsules
calcifediol
calcifediol soft
hypophosphatemia
osteoarthrosis
Prior art date
Application number
CY20201100484T
Other languages
English (en)
Inventor
Josep María SUÑÉ NEGRE
Ignacio Ortega Azpitarte
Pepa Del Arenal Barrios
Gonzalo HERNÁNDEZ HERRERO
Original Assignee
Faes Farma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122976(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma, S.A. filed Critical Faes Farma, S.A.
Publication of CY1122976T1 publication Critical patent/CY1122976T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μαλακές κάψουλες καλσιφεδιόλης, στη χρήση τους για την θεραπεία ή τη πρόληψη νοσημάτων που σχετίζονται με την έλλειψη βιταμίνης D, απομετάλλωση όπως υπασβεστιαιμία και υποφωσφαταιμία, νεφρική οστεοδυστροφία, ραχίτιδα, οστεοπόρωση, οστεοπενία, οστεοαρθρίτιδα, οστεοάρθρωση, οστεομαλακία, υποπαραθυρεοειδισμό, και φλεγμονώδη νόσο του εντέρου, και στις διαδικασίες για τη παρασκευή τους.
CY20201100484T 2015-02-06 2020-05-28 Μαλακες καψουλες καλσιφεδιολης CY1122976T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382042.8A EP3053598A1 (en) 2015-02-06 2015-02-06 Calcifediol soft capsules
PCT/EP2016/052458 WO2016124724A1 (en) 2015-02-06 2016-02-05 Calcifediol soft capsules

Publications (1)

Publication Number Publication Date
CY1122976T1 true CY1122976T1 (el) 2021-10-29

Family

ID=52462260

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100484T CY1122976T1 (el) 2015-02-06 2020-05-28 Μαλακες καψουλες καλσιφεδιολης

Country Status (31)

Country Link
US (1) US10525018B2 (el)
EP (3) EP3053598A1 (el)
JP (2) JP6427270B2 (el)
KR (1) KR101971384B1 (el)
CN (2) CN106999441B (el)
AU (1) AU2016214336B2 (el)
BR (1) BR112017010657B1 (el)
CA (1) CA2967170C (el)
CL (1) CL2017001335A1 (el)
CO (1) CO2017004545A2 (el)
CY (1) CY1122976T1 (el)
DK (2) DK3689380T3 (el)
EA (1) EA034821B1 (el)
ES (2) ES2941385T3 (el)
HR (1) HRP20200859T1 (el)
HU (1) HUE050133T2 (el)
LT (1) LT3204047T (el)
MA (2) MA52507A (el)
MD (1) MD3204047T2 (el)
ME (1) ME03739B (el)
MX (1) MX367999B (el)
MY (2) MY189432A (el)
PE (1) PE20170911A1 (el)
PH (1) PH12017501350A1 (el)
PL (1) PL3204047T3 (el)
PT (1) PT3204047T (el)
RS (2) RS64166B1 (el)
SI (1) SI3204047T1 (el)
SM (1) SMT202000278T1 (el)
WO (1) WO2016124724A1 (el)
ZA (1) ZA201703444B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
WO2021033003A1 (en) * 2019-08-22 2021-02-25 Industrial Technologies & Biotechnologies Hormone d (vitamin d) and its derivatives for the treatment and prevention of cancer
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022224001A1 (en) 2021-04-22 2022-10-27 Faes Farma, S.A. Universal dosage regime of 25-hydroxy vitamin d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN116350598A (zh) * 2021-12-28 2023-06-30 人福普克药业（武汉）有限公司 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
CN120282775A (zh) * 2022-12-14 2025-07-08 R·P·谢勒技术有限公司 软凝胶胶囊和制备软凝胶胶囊的方法
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法
CN121466026A (zh) * 2026-01-12 2026-02-06 厦门紫旭医药科技有限公司 一种双层软胶膜及其制备方法和应用与大装量胶囊

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
CN1179725C (zh) * 1999-08-31 2004-12-15 中外制药株式会社 软胶囊剂
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
JP2005515996A (ja) 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
AU2003230191A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
MXPA06014185A (es) 2004-06-07 2007-04-16 Strides Arcolab Ltd Composicion farmaceutica que contiene una solucion estable y clara de medicamento anti-inflmatorio en capsulas de gelatina blanda, y proceso para producirlo.
KR20080063790A (ko) 2005-09-26 2008-07-07 노바세아, 인크. 활성 비타민 ｄ 화합물을 이용하는 화학 요법 또는 방사선요법과 관련된 위장 및 방광 장애의 예방 및 치료
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
ES2593047T3 (es) * 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
US8501717B2 (en) * 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
EP2321273B1 (en) 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
WO2012047098A1 (en) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules

Also Published As

Publication number Publication date
CA2967170C (en) 2018-06-05
ES2738642T3 (es) 2020-11-06
EP3204047B1 (en) 2020-05-27
AU2016214336A1 (en) 2017-05-25
JP6697779B2 (ja) 2020-05-27
MA41058B1 (fr) 2020-05-29
CA2967170A1 (en) 2016-08-11
JP2018184458A (ja) 2018-11-22
US10525018B2 (en) 2020-01-07
PL3204047T3 (pl) 2020-08-24
CN106999441A (zh) 2017-08-01
SMT202000278T1 (it) 2020-07-08
US20170348249A1 (en) 2017-12-07
PT3204047T (pt) 2020-06-05
BR112017010657A2 (pt) 2018-02-14
EP3689380B1 (en) 2023-03-15
ME03739B (me) 2021-01-20
KR101971384B9 (ko) 2022-07-25
ES2738642T1 (es) 2020-01-24
CO2017004545A2 (es) 2017-08-31
EP3053598A1 (en) 2016-08-10
JP6427270B2 (ja) 2018-11-21
WO2016124724A1 (en) 2016-08-11
CN106999441B (zh) 2020-11-24
DK3204047T3 (da) 2020-06-02
LT3204047T (lt) 2020-07-10
MA52507A (fr) 2021-03-10
CN112843014A (zh) 2021-05-28
HRP20200859T1 (hr) 2020-08-21
CL2017001335A1 (es) 2018-01-19
KR101971384B1 (ko) 2019-04-22
RS64166B1 (sr) 2023-05-31
DK3689380T3 (da) 2023-05-22
MY189432A (en) 2022-02-11
EA034821B1 (ru) 2020-03-25
JP2017536358A (ja) 2017-12-07
EP3689380A1 (en) 2020-08-05
MY199862A (en) 2023-11-25
AU2016214336B2 (en) 2017-10-19
ES2941385T3 (es) 2023-05-22
ZA201703444B (en) 2019-09-25
PE20170911A1 (es) 2017-07-12
SI3204047T1 (sl) 2020-07-31
KR20170093123A (ko) 2017-08-14
EA201791097A1 (ru) 2017-08-31
MD3204047T2 (ro) 2020-06-30
BR112017010657B1 (pt) 2022-10-11
MX2017006272A (es) 2017-08-14
PH12017501350A1 (en) 2017-12-18
EP3204047A1 (en) 2017-08-16
RS60467B1 (sr) 2020-07-31
HUE050133T2 (hu) 2020-11-30
MX367999B (es) 2019-09-12
EP3204047B2 (en) 2026-05-06

Similar Documents

Publication Publication Date Title
CY1122976T1 (el) Μαλακες καψουλες καλσιφεδιολης
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CY1123853T1 (el) Ρυθμιστες nrf2
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MX2017015579A (es) Formas de dosificacion solidas de palbociclib.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001154A1 (es) Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras.
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
EA201791845A1 (ru) Твердые формы менахинолов
MX2016012620A (es) Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
BR112017011285A2 (pt) compostos intermediários para produzir ingredientes de perfumaria
CY1123394T1 (el) Φαρμακευτικη συνθεση
LT3474858T (lt) Dviejų komponentų kompozicija, apimanti acetilsalicilo rūgštį
MX389506B (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
CL2018001370A1 (es) Derivados novedosos de diamino piridina